Meeting
2016 ASCO Annual Meeting
Pharmacogenomic prediction of treatment-induced severe lung toxicity in Hodgkin lymphoma (HL).
Authors
Rebekah Karns
Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Rebekah Karns , Mayur Sarangdhar , Bruce Aronow , Mitali Basu , Cindy L. Schwartz , Kara M. Kelly , Debra L. Friedman , John Peter Perentesis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Hodgkin Lymphoma
Citation
J Clin Oncol 34, 2016 (suppl; abstr 7522)
DOI
10.1200/JCO.2016.34.15_suppl.7522
Abstract #
7522
Poster Bd #
78
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Sequential pembrolizumab (pembro) and chemotherapy (chemo) in newly diagnosed, early unfavorable, or advanced-stage classical Hodgkin lymphoma (cHL): The phase 2 KEYNOTE-C11 study.
First Author: Jane N. Winter
Poster
2019 ASCO Annual Meeting
Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667.
First Author: Christine Mauz-Körholz
Poster
2018 ASCO Annual Meeting
KEYNOTE-667: Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy.
First Author: Christine Mauz-Korholz
Poster
2017 ASCO Annual Meeting
Risk-adapted therapy utilizing upfront brentuximab vedotin (Bv) and rituximab (R) with reduced toxicity chemotherapy in children, adolescents, and young adults with Hodgkin lymphoma.
First Author: Jessica Hochberg